Advertisement

Topics

Alkermes ENLIGHTEN Hints At Efficacy Benefit But Weight Profile Still In Balance

09:00 EDT 30 Jun 2017 | SCRIP

The first Phase III trial results for Alkermes' combination product for schizophrenia ALKS 3831 show hints of added benefit over...

      

Related Stories

 

Original Article: Alkermes ENLIGHTEN Hints At Efficacy Benefit But Weight Profile Still In Balance

NEXT ARTICLE

More From BioPortfolio on "Alkermes ENLIGHTEN Hints At Efficacy Benefit But Weight Profile Still In Balance"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...